DRIO NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

DarioHealth Corp · Healthcare · Health Information Services

Open interactive chart View report data Download investor PDF
Latest close 7.79 USD
14.3% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -11.3% below the Trend Line and sits at 16.3% of its 52-week range. The latest completed week returned 14.3%, after a 10.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 60/100. Near-term considerations: earnings are due in 12d.

Setup score 39 out of 100
Latest Close 7.79 USD 24 Jul 2026
1W Return 14.3% latest completed week
4W Return 10.8% short-term follow-through
12W Return 6.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 3.7x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.51% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 14.3% Latest completed week; four-week move 10.8%. Indicator stack 0/79 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.51% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 60/100 47 relevant articles in the latest sentiment read. Event risk 12d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -11.3% below the Trend Line and sits at 16.3% of its 52-week range. The latest completed week returned 14.3%, after a 10.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 3.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1612-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 10.8% over four weeks, 6.7% over 12 weeks, and -40.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W14.3%
4W10.8%
12W6.7%
26W-33.1%
52W-40.2%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.51Latest activity-pressure read.
Pressure change246.9%Four-week change in activity pressure.
Leadership-29.75Latest relative-leadership reading.
RS change30.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength25/100Blend of value, momentum, and quality. Underlying universe rank 76; rank 1 is best.
Value70/100Relative valuation strength. Underlying universe rank 31; rank 1 is best.
Quality7/100Profitability and accounting quality. Underlying universe rank 94; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth13/100Revenue and earnings growth. Underlying universe rank 88; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
0.9x
Price divided by trailing earnings.
Price / sales
2.7x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-36.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
56.5%
Gross profit retained from each unit of revenue.
Operating margin
-161.8%
Operating profit retained from revenue.
Free-cash-flow margin
-118.7%
Free cash flow generated from revenue.
Return on invested capital
-46.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-24.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-42.4%
Net share repurchases relative to market value.
Shareholder yield
-42.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is neutral across 47 relevant articles.

21 positive · 21 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings12dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-56.1%Distance below the 52-week high.
13-week volatility5.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+17.8%Week of 13 Feb.
Worst week-19.0%Week of 6 Mar.
Latest week+14.3%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains6
Flat weeks0
Modest losses7
Sharp losses8
Recent vol5.7%13-week weekly-return volatility.
Base vol18.1%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew13.4% / -8.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape30/100

Trend, activity pressure, participation, and risk combine to a 30/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.16; No reversal markers Next-Week ExpectancyNegative 42.51%

Next-week expectancy is negative with a 42.51% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors26/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 37 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment60/100

Weighted news tone is neutral across 47 relevant articles.

DarioHealth Prices $23.5 Million Registered Direct Offering Insiders50/100

No recent insider transaction evidence is stored.

 Earnings12d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20267.79 USD14.3%8.78 USD21.27 USD0.51-29.75220.9KOff
17 Jul 20266.81 USD-5.6%8.86 USD21.70 USD0.36-40.3643.9KOff
10 Jul 20267.22 USD-0.8%9.01 USD22.19 USD0.18-40.4653.0KOff
3 Jul 20267.28 USD3.6%9.17 USD22.65 USD-0.02-39.9990.3KOff
26 Jun 20267.03 USD1.4%9.32 USD23.09 USD-0.35-42.54104.3KOff
19 Jun 20266.93 USD-1.8%9.49 USD23.56 USD-0.67-46.7715.1KOff
12 Jun 20267.06 USD-5.9%9.72 USD23.98 USD-0.80-45.3438.1KOff
5 Jun 20267.50 USD-3.2%9.87 USD24.45 USD-0.75-41.5741.5KOff
29 May 20267.75 USD-1.4%10.04 USD24.93 USD-0.79-43.2937.1KOff
22 May 20267.86 USD-5.3%10.25 USD25.40 USD-0.92-41.8622.0KOff
15 May 20268.30 USD6.3%10.53 USD25.84 USD-0.96-38.9452.1KOff
8 May 20267.81 USD7.0%10.68 USD26.27 USD-1.12-43.5123.9KOff
1 May 20267.30 USD-1.5%10.93 USD26.73 USD-1.10-45.3730.6KOff
24 Apr 20267.41 USD2.1%11.24 USD27.17 USD-0.99-44.7666.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.